3 active not recruiting, 3 completed, 1 recruiting, 1 withdrawn. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 3, Completed 3, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Refractory Lymphoplasmacytic Lymphoma: new trials by email Literature Review of Refractory Lymphoplasmacytic Lymphoma trials Research Report on Refractory Lymphoplasmacytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 39 | 2013-09-24 | 2026-05-13 |
Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (7) · Lymphoma, Large B-Cell, Diffuse (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (4) · Waldenstrom Macroglobulinemia (4) · Burkitt Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Erdheim-Chester Disease (1) · Histiocytic Sarcoma (1) · Histiocytosis, Langerhans-Cell (1) · Leukemia, Hairy Cell (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoma (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Hematologic Diseases (7) · Lymphoma, Non-Hodgkin (6) · Blood Protein Disorders (4) · Cardiovascular Diseases (4) · Chronic Disease (4) · Disease Attributes (4) · Hemorrhagic Disorders (4)
Lenalidomide (4) · ibrutinib (3) · Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Azacitidine (1) · Cyclophosphamide (1) · Immunotherapy, Adoptive (1) · LFB-R603 (1) · Leukapheresis (1) · Nivolumab (1) · Pharmacogenomic Variants (1) · cc-486 (1) · fludarabine phosphate (1) · obinutuzumab (1)
City of Hope Medical Center (1) · David Bond, MD (1) · Fred Hutchinson Cancer Center (1) · Joseph Tuscano (1) · Kami Maddocks (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Yazeed Sawalha (1)
United States (7) · Canada (1)
Alexey Danilov (1) · Beth A Christian (1) · David Bond, MD (1) · Jithma P. Abeykoon, MD (1) · Joseph M Tuscano (1) · Kami Maddocks, MD (1) · Mazyar Shadman (1) · Yazeed Sawalha, MD (1)
P30CA016058 (2), K24CA201524 (1), P30CA069533 (1), P30CA093373 (1), U01CA076576 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186705 (1), UM1CA186712 (1)